CanSino Biologics (CanSinoBIO) has achieved a regulatory milestone with China’s National Medical Products Administration (NMPA) formally accepting the New Drug Application (NDA) for its Tetanus, Reduced Diphtheria and Pertussis (Acellular, Five Components) combined vaccine, adsorbed, designed for people aged six years and above.

The vaccine, referred to as Td5cp Adolescent and Adult, is being developed as a booster vaccine for adolescents and adults and was granted Priority Review status by the NMPA in May 2026. 

If approved and commercialised, the product could expand CanSinoBIO’s pertussis-containing vaccine portfolio across different age groups and complement its recently approved three-component DTaP vaccine, Tripecia (DT3cP Infant).

The regulatory development comes against the backdrop of a resurgence in pertussis cases globally. 

In China, reported pertussis cases exceeded 470,000 in 2024, representing an approximately 12-fold increase from 2023. The rise has renewed attention on disease prevention and highlighted the importance of booster immunisation among adolescents and adults in addition to infant vaccination.

CanSinoBIO’s Td5cp Adolescent and Adult contains five pertussis antigens, including pertussis toxin (PT), filamentous haemagglutinin (FHA), pertactin (PRN), FIM2 and FIM3. 

The inclusion of FIM2 and FIM3 differentiates the candidate from the company’s three-component DT3cP vaccine, which contains PT, FHA and PRN.

According to the company, the individual purification of each pertussis antigen and formulation at defined ratios are intended to support product quality and batch-to-batch consistency.

The latest development follows the approval in April 2026 of CanSinoBIO’s Tripecia (DT3cP Infant) for infants through the NMPA’s Priority Review pathway. The approval represented a significant step forward for the company’s component-based pertussis vaccine platform.

The company’s pipeline expansion also comes as China places greater emphasis on life-course immunisation.

In July 2026, seven government departments, including the National Disease Control and Prevention Administration and the National Development and Reform Commission, jointly issued the 15th Five-Year Plan for Disease Prevention and Control, which calls for implementation of a life-course immunisation strategy covering the population across different stages of life.